Seattle Genetics, the Bothell, WA-based developer of targeted antibody drugs, said today it has started a mid-stage clinical trial of SGN-35 as a treatment for relapsed forms of anaplastic large cell lymphoma. The trial will enroll 55 patients, who will the same dose every three weeks as the one being used in an ongoing pivotal trial of Hodgkin’s disease and related lymphomas. The Seattle Genetics (NASDAQ: [[ticker:SGEN]]) drug is designed to be an “empowered antibody” that adds a potent toxin to an antibody to give it more tumor-killing punch.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
